Dallah Healthcare Company (4004.SR)
SAR 157.6
(0.38%)
SAR 157.6
(0.38%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 631.92 Million SAR | 22.12% |
| 2022 | 536.7 Million SAR | 18.21% |
| 2021 | 479.86 Million SAR | 109.15% |
| 2020 | 290.18 Million SAR | -14.98% |
| 2019 | 273.5 Million SAR | 10.51% |
| 2018 | 220.19 Million SAR | -38.73% |
| 2017 | 368.6 Million SAR | 21.84% |
| 2016 | 298.12 Million SAR | 30.55% |
| 2015 | 226.67 Million SAR | 17.88% |
| 2014 | 190.12 Million SAR | 11.03% |
| 2013 | 173.65 Million SAR | 9.01% |
| 2012 | 166.61 Million SAR | 12.39% |
| 2011 | 144.86 Million SAR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 199.45 Million SAR | 10.81% |
| 2024 Q2 | 170.18 Million SAR | -5.08% |
| 2023 Q3 | 170.54 Million SAR | 30.29% |
| 2023 Q4 | 185.24 Million SAR | 8.62% |
| 2023 FY | - SAR | 22.12% |
| 2023 Q1 | 170.72 Million SAR | 5.44% |
| 2023 Q2 | 130.89 Million SAR | -23.33% |
| 2022 Q2 | 123.68 Million SAR | -10.16% |
| 2022 Q4 | 161.91 Million SAR | 40.81% |
| 2022 Q3 | 114.99 Million SAR | -7.03% |
| 2022 Q1 | 137.68 Million SAR | -14.64% |
| 2022 FY | - SAR | 18.21% |
| 2021 Q1 | 95.44 Million SAR | 49.86% |
| 2021 Q4 | 161.3 Million SAR | 64.85% |
| 2021 FY | - SAR | 109.15% |
| 2021 Q2 | 95.05 Million SAR | -0.4% |
| 2021 Q3 | 97.84 Million SAR | 2.93% |
| 2020 Q2 | 33.38 Million SAR | -34.29% |
| 2020 Q3 | 69.85 Million SAR | 109.26% |
| 2020 FY | - SAR | -14.98% |
| 2020 Q4 | 63.68 Million SAR | -8.83% |
| 2020 Q1 | 50.79 Million SAR | -49.72% |
| 2019 Q3 | 54.5 Million SAR | 18.76% |
| 2019 FY | - SAR | 10.51% |
| 2019 Q1 | 67.96 Million SAR | 14.73% |
| 2019 Q2 | 45.89 Million SAR | -32.48% |
| 2019 Q4 | 101.02 Million SAR | 85.35% |
| 2018 Q2 | 21.7 Million SAR | -71.63% |
| 2018 FY | - SAR | -38.73% |
| 2018 Q4 | 59.24 Million SAR | 61.79% |
| 2018 Q3 | 36.61 Million SAR | 68.7% |
| 2018 Q1 | 76.51 Million SAR | -15.18% |
| 2017 Q1 | 101.27 Million SAR | 24.84% |
| 2017 FY | - SAR | 21.84% |
| 2017 Q4 | 90.21 Million SAR | -1.08% |
| 2017 Q2 | 91.49 Million SAR | -9.66% |
| 2017 Q3 | 91.19 Million SAR | -0.33% |
| 2016 Q4 | 81.11 Million SAR | 3.34% |
| 2016 FY | - SAR | 30.55% |
| 2016 Q1 | 76.43 Million SAR | -0.16% |
| 2016 Q2 | 74.34 Million SAR | -2.74% |
| 2016 Q3 | 78.49 Million SAR | 5.59% |
| 2015 FY | - SAR | 17.88% |
| 2015 Q4 | 76.55 Million SAR | 75.07% |
| 2015 Q3 | 43.73 Million SAR | -16.1% |
| 2015 Q2 | 52.12 Million SAR | -17.6% |
| 2015 Q1 | 63.25 Million SAR | -5.18% |
| 2014 FY | - SAR | 11.03% |
| 2014 Q3 | 34.7 Million SAR | -26.43% |
| 2014 Q2 | 47.17 Million SAR | -7.12% |
| 2014 Q1 | 50.79 Million SAR | -17.85% |
| 2014 Q4 | 66.71 Million SAR | 92.19% |
| 2013 Q2 | 41.65 Million SAR | -10.48% |
| 2013 Q3 | 32.42 Million SAR | -22.14% |
| 2013 FY | - SAR | 9.01% |
| 2013 Q4 | 61.83 Million SAR | 90.67% |
| 2013 Q1 | 46.52 Million SAR | 2.12% |
| 2012 Q4 | 45.56 Million SAR | 46.47% |
| 2012 Q2 | 46.69 Million SAR | 3.96% |
| 2012 FY | - SAR | 12.39% |
| 2012 Q1 | 44.91 Million SAR | -14.89% |
| 2012 Q3 | 31.1 Million SAR | -33.38% |
| 2011 Q3 | 16.89 Million SAR | 0.0% |
| 2011 FY | - SAR | 0.0% |
| 2011 Q4 | 52.77 Million SAR | 212.32% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Mouwasat Medical Services Company | 986.81 Million SAR | 35.963% |
| National Medical Care Company | 323.02 Million SAR | -95.63% |
| Al Hammadi Company For Development and Investment | 438.27 Million SAR | -44.184% |
| Middle East Healthcare Company | 551.23 Million SAR | -14.638% |
| Dr. Sulaiman Al Habib Medical Services Group Company | 2.54 Billion SAR | 75.164% |
| Canadian General Medical Center Complex Company | 19.92 Million SAR | -3071.77% |
| Arabian International Healthcare Holding Company | 111.1 Million SAR | -468.758% |
| Future Care Trading Co. | 15.6 Million SAR | -3948.709% |
| Naba Alsaha Medical Services Company | 65.27 Million SAR | -868.036% |
| Lana Medical Co. | 4.56 Million SAR | -13735.52% |
| Al-Modawat Specialized Medical Co. | 20.76 Million SAR | -2942.72% |